Doctor of Osteopathy Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Mark Gardner

Orthopaedic Surgery Hermitage, PA Doctor of Osteopathy

NPI 1467766022 CMS profile 339386

1599 N Hermitage Rd, Hermitage, PA 16148

Open in the dashboard

General payments

$18,763

131 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Mark Gardner of Hermitage, PA is reported in the CMS Open Payments database as having received $18,763 across 131 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 79th percentile of Orthopaedic Surgery profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

6 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,209 10
2024 General $3,786 43
2023 General $997 10
2022 General $6,055 32
2020 General $1,721 16
2019 General $4,995 20

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Mark Gardner
  • Orthopaedic Surgery median
  • Middle half of Orthopaedic Surgery
  • National median

In program year 2025, general payments to Mark Gardner were reported at $1,209. Among 15,343 Orthopaedic Surgery profiles paid that year, the median was $563 and the middle half received between $147 and $2,717.

Show as a table
Year Mark Gardner Orthopaedic Surgery median Middle half National median
2019 $4,995 $644 $140–$2,844 $163
2020 $1,721 $312 $75–$1,860 $114
2021 $0 $520 $117–$2,495 $132
2022 $6,055 $598 $128–$2,731 $149
2023 $997 $461 $128–$2,264 $160
2024 $3,786 $497 $134–$2,475 $164
2025 $1,209 $563 $147–$2,717 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Arthrex, Inc. $10,141 66 payments
  2. Smith+Nephew, Inc. $3,097 17 payments
  3. Stryker Corporation $2,932 37 payments
  4. Mid-Atlantic Surgical Systems, LLC $2,507 10 payments
  5. Bioventus LLC $87 1 payment

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Travel and Lodging $10,114 33 payments
  2. Food and Beverage $4,936 95 payments
  3. Education $3,713 3 payments
Products named General payments · program years 2019–2025
  1. MAKO $2,708 34 payments
  2. Navio Surgical System $2,523 13 payments
  3. REAL INTELLIGENCE $380 2 payments
  4. HIP7 $330 1 payment
  5. INSIGNIA $171 1 payment
  6. NAVIO $141 1 payment
  7. Journey II XR $141 1 payment
  8. EXOGEN ULTRASOUND BONE HEALING SYSTEM $87 1 payment
  9. REGENETEN $53 1 payment
  10. RI Hip Navigation $50 1 payment
  11. Other $186 6 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 11 drugs

Part D claims

687

Median for Orthopedic Surgery: 203

Drug cost

$2,413

Median for Orthopedic Surgery: $1,433

Branded share of claims

0%

Median for Orthopedic Surgery: 11.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Meloxicam Generic 248 $761
Diclofenac Sodium Generic 34 $461
Methylprednisolone Generic 79 $334
Celecoxib Generic 11 $222
Naproxen Generic 14 $145
Tramadol Hcl Generic 45 $135
Amoxicillin Generic 166 $123
Mupirocin Generic 20 $104
Clindamycin Hcl Generic 44 $46
Gabapentin Generic 11 $42

The 10 drugs with the highest cost, of 11 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 18,934 Part D prescribers listed as Orthopedic Surgery; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 87 billing codes

Paid by Medicare

$274,162

Of which drugs: $20,690

Medicare patients

562

Average age 75

Services billed

2,988

363 women, 199 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 75%
Ischemic heart disease 27%
Diabetes 25%
Depression 24%
Chronic kidney disease 23%
Atrial fibrillation 20%
Osteoporosis 20%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Hyaluronan or derivative, euflexxa, for intra-articular injection, per dose J7323 Office 33 110 $10,397
Hyaluronan or derivative, hyalgan, supartz or visco-3, for intra-articular injection, per dose J7321 Office 23 97 $5,568
Injection, triamcinolone acetonide, not otherwise specified, 10 mg J3301 Office 233 529 $386

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

131 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Orthopaedic Surgery in Pennsylvania

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record